294 related articles for article (PubMed ID: 11678173)
1. Homozygous disruption of the mdrla P-glycoprotein gene affects blood-nerve barrier function in mice administered with neurotoxic drugs.
Saito T; Zhang ZJ; Ohtsubo T; Noda I; Shibamori Y; Yamamoto T; Saito H
Acta Otolaryngol; 2001 Sep; 121(6):735-42. PubMed ID: 11678173
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory effect of cyclosporin A on p-glycoprotein function in peripheral nerves of mice treated with doxorubicin and vinblastine.
Saito T; Zhang ZJ; Ohtsubo T; Noda I; Tokuriki M; Shibamori Y; Yamamoto T; Saito H
Acta Otolaryngol; 2004 Apr; 124(3):313-7. PubMed ID: 15141761
[TBL] [Abstract][Full Text] [Related]
3. Disruption of mdr1a p-glycoprotein gene results in dysfunction of blood-inner ear barrier in mice.
Zhang ZJ; Saito T; Kimura Y; Sugimoto C; Ohtsubo T; Saito H
Brain Res; 2000 Jan; 852(1):116-26. PubMed ID: 10661503
[TBL] [Abstract][Full Text] [Related]
4. Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier.
Cisternino S; Mercier C; Bourasset F; Roux F; Scherrmann JM
Cancer Res; 2004 May; 64(9):3296-301. PubMed ID: 15126373
[TBL] [Abstract][Full Text] [Related]
5. Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice.
van Asperen J; Schinkel AH; Beijnen JH; Nooijen WJ; Borst P; van Tellingen O
J Natl Cancer Inst; 1996 Jul; 88(14):994-9. PubMed ID: 8667431
[TBL] [Abstract][Full Text] [Related]
6. Resolution of P-glycoprotein and non-P-glycoprotein effects on drug permeability using intestinal tissues from mdr1a (-/-) mice.
Stephens RH; O'Neill CA; Bennett J; Humphrey M; Henry B; Rowland M; Warhurst G
Br J Pharmacol; 2002 Apr; 135(8):2038-46. PubMed ID: 11959808
[TBL] [Abstract][Full Text] [Related]
7. Puromycin selectively increases mdr1a expression in immortalized rat brain endothelial cell lines.
Demeuse P; Fragner P; Leroy-Noury C; Mercier C; Payen L; Fardel O; Couraud PO; Roux F
J Neurochem; 2004 Jan; 88(1):23-31. PubMed ID: 14675146
[TBL] [Abstract][Full Text] [Related]
8. Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system.
Sane R; Agarwal S; Mittapalli RK; Elmquist WF
J Pharmacol Exp Ther; 2013 Apr; 345(1):111-24. PubMed ID: 23397054
[TBL] [Abstract][Full Text] [Related]
9. Screening of multidrug-resistance sensitive drugs by in situ brain perfusion in P-glycoprotein-deficient mice.
Cisternino S; Rousselle C; Dagenais C; Scherrmann JM
Pharm Res; 2001 Feb; 18(2):183-90. PubMed ID: 11405289
[TBL] [Abstract][Full Text] [Related]
10. P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor.
Yang JJ; Milton MN; Yu S; Liao M; Liu N; Wu JT; Gan L; Balani SK; Lee FW; Prakash S; Xia CQ
Drug Metab Lett; 2010 Dec; 4(4):201-12. PubMed ID: 20670210
[TBL] [Abstract][Full Text] [Related]
11. Comparative pharmacokinetics of vinblastine after a 96-hour continuous infusion in wild-type mice and mice lacking mdr1a P-glycoprotein.
van Asperen J; van Tellingen O; Schinkel AH; Beijnen JH
J Pharmacol Exp Ther; 1999 Apr; 289(1):329-33. PubMed ID: 10087021
[TBL] [Abstract][Full Text] [Related]
12. Characterisation of the brain multidrug resistance protein (BMDP/ABCG2/BCRP) expressed at the blood-brain barrier.
Eisenblätter T; Hüwel S; Galla HJ
Brain Res; 2003 May; 971(2):221-31. PubMed ID: 12706238
[TBL] [Abstract][Full Text] [Related]
13. Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier.
Bihorel S; Camenisch G; Lemaire M; Scherrmann JM
J Neurochem; 2007 Sep; 102(6):1749-1757. PubMed ID: 17696988
[TBL] [Abstract][Full Text] [Related]
14. What kinds of substrates show P-glycoprotein-dependent intestinal absorption? Comparison of verapamil with vinblastine.
Ogihara T; Kamiya M; Ozawa M; Fujita T; Yamamoto A; Yamashita S; Ohnishi S; Isomura Y
Drug Metab Pharmacokinet; 2006 Jun; 21(3):238-44. PubMed ID: 16858128
[TBL] [Abstract][Full Text] [Related]
15. Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption.
Uhr M; Grauer MT; Holsboer F
Biol Psychiatry; 2003 Oct; 54(8):840-6. PubMed ID: 14550684
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic assessment of efflux transport in sunitinib distribution to the brain.
Oberoi RK; Mittapalli RK; Elmquist WF
J Pharmacol Exp Ther; 2013 Dec; 347(3):755-64. PubMed ID: 24113148
[TBL] [Abstract][Full Text] [Related]
17. Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid.
Shen J; Carcaboso AM; Hubbard KE; Tagen M; Wynn HG; Panetta JC; Waters CM; Elmeliegy MA; Stewart CF
Cancer Res; 2009 Jul; 69(14):5885-92. PubMed ID: 19567673
[TBL] [Abstract][Full Text] [Related]
18. Functional expression of P-glycoprotein and multidrug resistance-associated protein (Mrp1) in primary cultures of rat astrocytes.
Declèves X; Regina A; Laplanche JL; Roux F; Boval B; Launay JM; Scherrmann JM
J Neurosci Res; 2000 Jun; 60(5):594-601. PubMed ID: 10820430
[TBL] [Abstract][Full Text] [Related]
19. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs.
Schinkel AH; Smit JJ; van Tellingen O; Beijnen JH; Wagenaar E; van Deemter L; Mol CA; van der Valk MA; Robanus-Maandag EC; te Riele HP
Cell; 1994 May; 77(4):491-502. PubMed ID: 7910522
[TBL] [Abstract][Full Text] [Related]
20. P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib.
Chen Y; Agarwal S; Shaik NM; Chen C; Yang Z; Elmquist WF
J Pharmacol Exp Ther; 2009 Sep; 330(3):956-63. PubMed ID: 19491323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
